Q-omics provides the consensus-scored SMIM21 profile across patient tissues and cancer cell-line models. SMIM21 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SMIM21 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, SMIM21 RNA expression shows 6,750 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, KIRC, and STAD as cancer lineages where SMIM21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM21 survival associations across molecular data types. SMIM21 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM21 RNA expression–survival associations across cancer types. High SMIM21 expression shows unfavorable associations in LUSC, KIRC, SCLC, READ and ESCA, but favorable associations in UCS. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for SMIM21 RNA expression.
This table summarizes SMIM21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM21 shows lower tumor expression in KIRC, KICH, KIRP and BRCA and higher tumor expression in HNSC and LUAD. The KIRC box plot shows higher SMIM21 RNA expression in normal versus tumor tissue (log2 FC = −0.025, t-test p < 0.001).
This table shows molecular features associated with SMIM21 in patient tissues and cancer cell lines. In patient samples, SMIM21 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SOFT_TISSUE.
